Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 259

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 259
---
4, the Company                                                                                                            
 renewed its facility lease agreement until December 2024. The monthly rental obligations under non-cancellable leases are approximately 
 $5.5 (including $3 for administrative expenses).                                                                                        |

As part of the agreement, the Company
has provided the landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2025.

<div align='center'>F-13</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

Future minimum lease payments under non-cancelable
operating leases as of June 30, 2024 are as follows:

| 2024 |     | USD | 33 |
|:-----|:----|:----|---:|
|      |     | $   | 33 |

The Company elected to apply the practical
expedients permitted under the transition guidance in ASU 2016-02, and the Company also elected not to apply the recognition requirements
in ASU 2016-02 to short-term leases (less than 12 months) as of the adoption date. As such, there was no impact on the Company’s
financial statements as a result of adopting ASU 2016-02.

| 6. | In 2019, a controversy                                                                                                                                                   
 has arisen between the Company and CSL Behring GmbH, or CSL, whether certain unshipped minimum purchase commitments for fibrinogen                                       
 from 2018 to 2020 are to be paid by the Company pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework Supply                                        
 Agreement, by and between the Company and CSL, whereby CSL agreed to supply the Company with fibrinogen. On January 14, 2020, the                                        
 Company received a termination letter, or CSL Termination Letter. In the CSL Termination Letter, CSL demanded a total amount of $820,                                    
 claiming it was owed the minimum purchase commitment amounts under the Framework Supply Agreement not paid by the Company in 2018                                        
 and 2019. In a subsequent correspondence, CSL additionally demanded interest and damages for lost profit, with an aggregate demand                                       
 amount of $1,476. The Company has disputed CSL’s payment demand and contends that CSL’s demands are baseless